Outcomes | No of Participants (studies) Follow up | Quality of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
---|---|---|---|---|---|
Risk with Control | Risk difference with Objective Response Rate (95% CI) | ||||
Objective Response Rate | 2143 (4 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 1.11 (1.03 to 1.19) | Study population | |
534 ORR per 100 | 59 more per 1000 (from 16 more to 101 more) | ||||
Moderate | |||||
513 ORR per 1000 | 56 more per 1000 (from 15 more to 97 more) | ||||
Disease Control Rate | 1006 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 0.95 (0.90 to 1.00) | Study population | |
872 DCR per 1000 | 44 fewer per 1000 (from 87 fewer to 0 more) | ||||
Moderate | |||||
868 DCR per 1000 | 43 fewer per 1000 (from 87 fewer to 0 more) | ||||
Complete response | 1006 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 3.21 (1.27 to 8.12) | Study population | |
11 CR per 1000 | 24 more per 1000 (from 3 more to 77 more) | ||||
Moderate | |||||
14 CR per 1000 | 31 more per 1000 (from 4 more to 100 more) | ||||
Partial response | 1006 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 1.10 (0.98 to 1.23) | Study population | |
505 PR per 1000 | 50 more per 1000 (from 10 fewer to 116 more) | ||||
Moderate | |||||
458 PR per 1000 | 46 more per 1000 (from 9 fewer to 105 more) | ||||
Stable disease | 1006 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 0.66 (0.54 to 0.81) | Study population | |
357 per 1000 | 121 fewer per 1000 (from 68 fewer to 164 fewer) | ||||
Moderate | |||||
431 per 1000 | 147 fewer per 1000 (from 82 fewer to 198 fewer) | ||||
Progressive disease | 1006 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | |||
RR 1.31 (0.84 to 2.05) | 65 PD per 1000 | 20 more per 1000 (from 10 fewer to 68 more) | |||
Moderate | |||||
69 PD per 1000 | 21 more per 1000 (from 11 fewer to 72 more) | ||||
Early objective response rate | 330 (1 studie) | ⊕ ⊕ ⊕⊝MODERATE1 | RR 1.40 (1.16 to 1.68) | Study population | |
491 per 1000 | 197 more per 1000 (from 79 more to 334 more) | ||||
Moderate | |||||
491 per 1000 | 196 more per 1000 (from 79 more to 334 more) | ||||
Hematologic Adverse Events | 1586 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 1.00 (0.86 to 1.16) | Study population | |
308HAE per 1000 | 0 fewer per 1000 (from 43 fewer to 49 more) | ||||
Moderate | |||||
326 HAE per 1000 | 0 fewer per 1000 (from 46 fewer to 52 more) | ||||
Nonhematologic Adverse Events | 1586 (3 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 1.24 (1.02 to 1.52) | Study population | |
175 NHAE per 1000 | 42 more per 1000 (from 3 more to 91 more) | ||||
Moderate | |||||
147 NHAE per 1000 | 35 more per 1000 (from 3 more to 76 more) | ||||
curative intent | 1426 (2 studies) | ⊕ ⊕ ⊕⊝MODERATE | RR 1.47 (1.55 to 1.88) | Study population | |
124 per 1000 | 59 more per 1000 (from 19 more to 110 more) | ||||
Moderate | |||||
117 per 1000 | 59 more per 1000 (from 19 more to 110 more) | ||||
Overall survival | 2576 (5 studies) | ⊕ ⊕ ⊕⊝MODERATE | HR 0.89 (0.81 to 0.98) | ||
Progression free survival | 2576 (5 studies) | ⊕ ⊕ ⊕⊝MODERATE | HR 0.97 (0.90 to 1.05) |